Mueller-Eckhardt G, Heine O, Turba H, Berghöfer A, Neppert J, Künzel W, Mueller-Eckhardt C
Institut für Klinische Immunologie und Transfusionsmedizin, Justus-Liebig-Universität Giessen.
Beitr Infusionsther. 1990;26:298-301.
Intravenous immunoglobulins (IVIG) were used in an alternative approach to immunotherapy with allogeneic leukocytes to prevent recurrent spontaneous abortions (RSA). Twenty five women with a history of greater than or equal to 3 unexplained RSA were treated with IVIG during their next pregnancy. An initial dose of 30 g (0.5-0.6 g/kg body weight) was administered at gestational week 5-6. Treatment was continued every 3 weeks with 20 g (0.3-0.4 g/kg) and terminated by week 25. In primary RSA the success rate was 82-85%, which is in the same range as for leukocyte therapy. In contrast, IVIG was successful in only 40% of secondary aborters. We conclude that IVIG can be an effective treatment for prevention of primary RSA. Compared to leukocyte therapy the risks of transmission of infections and of HLA immunization can be avoided.
静脉注射免疫球蛋白（IVIG）被用于一种替代同种异体白细胞免疫疗法的方法，以预防复发性自然流产（RSA）。25名有≥3次不明原因RSA病史的女性在下次怀孕时接受了IVIG治疗。在妊娠第5 - 6周给予初始剂量30 g（0.5 - 0.6 g/kg体重）。每3周继续给予20 g（0.3 - 0.4 g/kg）治疗，至第25周结束。在原发性RSA中，成功率为82 - 85%，与白细胞疗法的成功率处于同一范围。相比之下，IVIG仅在40%的继发性流产者中取得成功。我们得出结论，IVIG可以作为预防原发性RSA的有效治疗方法。与白细胞疗法相比，可以避免感染传播和HLA免疫的风险。
